Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models

OBJECTIVE: To investigate the anti-carcinogenic effect of metronomic Celecoxib (i.e., frequent administration in clinically available doses) against hepatocellular carcinoma (HCC) in the perspective of metastasis, spontaneous hepatocarcinogenesis, cancer invasion, proliferation, and stemness in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Chun-Chieh, Liao, Pei-Ying, Pandey, Sudhir, Yung, Su-Yung, Lai, Hsueh-Chou, Jeng, Long-Bin, Chang, Wei-Chun, Ma, Wen-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609882/
https://www.ncbi.nlm.nih.gov/pubmed/33194674
http://dx.doi.org/10.3389/fonc.2020.572861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609882/
https://www.ncbi.nlm.nih.gov/pubmed/33194674
http://dx.doi.org/10.3389/fonc.2020.572861

Ejemplares similares